SlideShare a Scribd company logo
1 of 58
IDSA GUIDELINES 
Practice Guidelines for the 
Diagnosis and Management of 
Skin and Soft Tissue Infections: 
2014 Update by the Infectious 
Diseases Society of America 
Clinical Infectious Diseases 2014; 59(2):147–59
What Is the Appropriate 
Evaluation and Treatment for 
Purulent SSTIs (Cutaneous 
Abscesses, Furuncles, 
Carbuncles, and Inflamed 
Epidermoid Cysts)?
Gram stain and culture of pus from 
carbuncles and abscesses are 
recommended, but treatment without 
these studies is reasonable in typical 
cases (strong, moderate).
Gram stain and culture of pus from inflamed 
epidermoid cysts are not recommended 
(strong, moderate).
Incision and drainage is the 
recommended treatment for inflamed 
epidermoid cysts, carbuncles, abscesses, 
and large furuncles, mild (strong, high).
The decision to administer antibiotics directed 
against S. aureus as an adjunct to incision 
and drainage should be made based upon 
presence or absence of systemic inflammatory 
response syndrome (SIRS), such as 
temperature >38℃ or <36℃, tachypnea >24 
bpm, tachycardia >90 bpm, or WBC >12000 or 
< 400 cells/μL (moderate) (strong, low). 
An antibiotic active against MRSA is 
recommended for patients with carbuncles or 
abscesses who have failed initial antibiotic 
treatment or have markedly impaired host 
defenses or in patients with SIRS and 
hypotension (severe) (strong, low).
What Is Appropriate for the 
Evaluation and Treatment of 
Erysipelas and Cellulitis?
Cultures of blood or cutaneous aspirates, 
biopsies, or swabs are not routinely 
recommended (strong, moderate).
Cultures of blood are recommended 
(strong, moderate), and cultures and 
microscopic examination of cutaneous 
aspirates, biopsies, or swabs should be 
considered in patients with malignancy 
on chemotherapy, neutropenia, severe 
cell-mediated immunodeficiency, 
immersion injuries, and animal bites 
(weak, moderate).
Typical cases of cellulitis without systemic signs of infection 
should receive an antimicrobial agent that is active against 
streptococci (mild) (strong, moderate). 
For cellulitis with systemic signs of infection (moderate 
nonpurulent), systemic antibiotics are indicated. Many 
clinicians could include coverage against MSSA (weak, low). 
For patients whose cellulitis is associated with penetrating 
trauma, evidence of MRSA infection elsewhere, nasal 
colonization with MRSA, injection drug use, or SIRS 
(severe nonpurulent), vancomycin or another antimicrobial 
effective against both MRSA and streptococci is 
recommended (strong, moderate). 
In severely compromised patients (severe nonpurulent), 
broad-spectrum antimicrobial coverage may be considered 
(weak, moderate). Vancomycin plus either piperacillin-tazobactam 
or imipenem/meropenem is recommended as 
a reasonable empiric regimen for severe 
infections (strong, moderate).
The recommended duration of antimicrobial 
therapy is 5 days, but treatment should 
be extended if the infection has not 
improved within this time period (strong, 
high).
In lower-extremity cellulitis, clinicians should 
carefully examine the interdigital toe 
spaces because treating fissuring, scaling, 
or maceration may eradicate colonization 
with pathogens and reduce the incidence 
of recurrent infection (strong, moderate).
Outpatient therapy is recommended for 
patients who do not have SIRS, altered 
mental status, or hemodynamic instability 
(mild nonpurulent) (strong, moderate). 
Hospitalization is recommended if there is 
concern for a deeper or necrotizing infection, 
for patients with poor adherence to therapy, 
for infection in a severely 
immunocompromised patient, or if outpatient 
treatment is failing (moderate or severe 
nonpurulent) (strong, moderate).
Should Anti-inflammatory Agents 
Be Used to Complement 
Antibiotic Treatment of 
Cellulitis?
Systemic corticosteroids (eg, prednisone 
40 mg daily for 7 days) could be 
considered in nondiabetic adult patients 
with cellulitis (weak, moderate).
What Is the Preferred Evaluation 
and Management of Patients 
With Recurrent Cellulitis?
Identify and treat predisposing conditions 
such as edema, obesity, eczema, venous 
insufficiency, and toe web abnormalities 
(strong, moderate). These practices 
should be performed as part of routine 
patient care and certainly during the acute 
stage of cellulitis (strong, moderate).
Administration of prophylactic antibiotics, 
such as oral penicillin or erythromycin bid 
for 4–52 weeks, or intramuscular 
benzathine penicillin every 2–4 weeks, 
should be considered in patients who have 
3–4 episodes of cellulitis per year despite 
attempts to treat or control predisposing 
factors (weak, moderate). This program 
should be continued so long as the 
predisposing factors persist (strong, 
moderate).
What Is the Preferred 
Management of Surgical Site 
Infections?
Suture removal plus I&D should be 
performed for surgical site infections 
(strong, low).
Adjunctive systemic antimicrobial therapy is 
not routinely indicated, but in conjunction 
with I&D may be beneficial for surgical 
site infections associated with a 
significant systemic response, such as 
erythema and induration extending >5 cm 
from the wound edge, temperature>38.5℃, 
heart rate >110 bpm, or WBC >12 000/μL 
(weak, low).
A brief course of systemic antimicrobial 
therapy is indicated in patients with 
surgical site infections following clean 
operations on the trunk, head and neck, 
or extremities that also have systemic 
signs of infection (strong, low).
A first-generation cephalosporin or an anti-staphylococcal 
penicillin for MSSA, or 
vancomycin, linezolid, daptomycin, 
telavancin, or ceftaroline where risk factors 
for MRSA are high (nasal colonization, 
prior MRSA infection, recent 
hospitalization, recent antibiotics), is 
recommended (strong, low).
Agents active against gram-negative 
bacteria and anaerobes, such as a 
cephalosporin or fluoroquinolone in 
combination with metronidazole, are 
recommended for infections following 
operations on the axilla, GI tract, 
perineum, or female genital tract (strong, 
low).
What Is the Preferred Evaluation 
and Treatment of Necrotizing 
Fasciitis, Including Fournier 
Gangrene?
Prompt surgical consultation is 
recommended for patients with aggressive 
infections associated with signs of 
systemic toxicity or suspicion of 
necrotizing fasciitis or gas gangrene 
(severe nonpurulent) (strong, low).
Empiric antibiotic treatment should be broad 
(eg, vancomycin or linezolid plus 
piperacillin-tazobactam or a carbapenem; 
or plus ceftriaxone and metronidazole), as 
the etiology can be poly-microbial (mixed 
aerobic–anaerobic microbes) or mono-microbial 
(group A streptococci, 
community-acquired MRSA) (strong, low).
Penicillin plus clindamycin is recommended 
for treatment of documented group A 
streptococcal necrotizing fasciitis (strong, 
low).
What Is the Appropriate 
Approach to the Management 
of Pyomyositis?
MRI is the recommended imaging modality 
for establishing the diagnosis of 
pyomyositis. CT and ultrasound studies 
are also useful (strong, moderate).
Cultures of blood and abscess material 
should be obtained (strong, moderate).
Vancomycin is recommended for initial 
empirical therapy. An agent active against 
enteric gram-negative bacilli should be 
added for infection in immuno-compromised 
patients or following open 
trauma to the muscles (strong, moderate).
Cefazolin or anti-staphylococcal penicillin 
(eg, nafcillin or oxacillin) is recommended 
for treatment of pyomyositis caused by 
MSSA (strong, moderate).
Early drainage of purulent material should 
be performed (strong, high).
Repeat imaging studies should be 
performed in the patient with persistent 
bacteremia to identify undrained foci of 
infection (strong, low).
Antibiotics should be administered 
intravenously initially, but once the patient 
is clinically improved, oral antibiotics are 
appropriate for patients in whom 
bacteremia cleared promptly and there is 
no evidence of endocarditis or metastatic 
abscess. Two to 3 weeks of therapy is 
recommended (strong, low).
What Is the Appropriate 
Approach to the Evaluation and 
Treatment of Clostridial Gas 
Gangrene or Myonecrosis?
Urgent surgical exploration of the 
suspected gas gangrene site and surgical 
debridement of involved tissue should be 
performed (severe nonpurulent) (strong, 
moderate).
In the absence of a definitive etiologic 
diagnosis, broadspectrum treatment with 
vancomycin plus either 
piperacillin/tazobactam, 
ampicillin/sulbactam, or a carbapenem 
antimicrobial is recommended (strong, 
low). Definitive antimicrobial therapy with 
penicillin and clindamycin is recommended 
for treatment of clostridial myonecrosis 
(strong, low).
Hyperbaric oxygen (HBO) therapy is 
not recommended because it has not 
been proven as a benefit to the patient 
and may delay resuscitation and surgical 
debridement (strong, low).
What Is the Role of Preemptive 
Antimicrobial Therapy to 
Prevent Infection for Dog or Cat 
Bites?
Preemptive early antimicrobial therapy for 
3–5 days is recommended for patients 
who 
a) are immunocompromised 
b) are asplenic 
c) have advanced liver disease 
d) have preexisting or resultant edema of the 
affected area 
e) have moderate to severe injuries, especially 
to the hand or face 
f) have injuries that may have penetrated the 
periosteum or joint capsule (strong, low).
Postexposure prophylaxis for rabies may be 
indicated;consultation with local health 
officials is recommended to determine if 
vaccination should be initiated (strong, 
low).
What Is the Treatment for 
Infected Animal Bite–Related 
Wounds?
An antimicrobial agent or agents active 
against both aerobic and anaerobic 
bacteria such as amoxicillin-clavulanate 
should be used (strong, moderate).
Should Tetanus Toxoid Be 
Administered for Animal Bite 
Wounds?
Tetanus toxoid should be administered to 
patients without toxoid vaccination within 
10 years. Tetanus, diptheria, and tetanus 
(Tdap) is preferred over Tetanus and 
diptheria (Td) if the former has not been 
previously given (strong, low).
In Which Patients Is Primary 
Wound Closure Appropriate for 
Animal Bite Wounds?
Primary wound closure is not recommended 
for wounds, with the exception of those to 
the face, which should be managed with 
copious irrigation, cautious debridement, 
and preemptive antibiotics (strong, low). 
Other wounds may be approximated 
(weak, low).
Management of Skin and Soft Tissue Infections: IDSA Guideline 2014

More Related Content

What's hot

Spontaneous Bacterial peritonitis
Spontaneous Bacterial peritonitisSpontaneous Bacterial peritonitis
Spontaneous Bacterial peritonitisBabar Rafique
 
HYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCYHYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCYAbhinav Srivastava
 
catheter related blood stream infections-complete material
catheter related blood stream infections-complete materialcatheter related blood stream infections-complete material
catheter related blood stream infections-complete materialRahul Arya
 
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EHAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EDr Sandeep Kumar
 
hemodialysis catheter infection
hemodialysis catheter infectionhemodialysis catheter infection
hemodialysis catheter infectionMuhamed Al Rohani
 
RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS(RPGN)
RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS(RPGN)RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS(RPGN)
RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS(RPGN)Manjunath Anvekar
 
Fever of unkown origin
Fever of unkown originFever of unkown origin
Fever of unkown originikramdr01
 
Heparin Induced Thrombocytopeia (HIT)
Heparin Induced Thrombocytopeia (HIT)Heparin Induced Thrombocytopeia (HIT)
Heparin Induced Thrombocytopeia (HIT)Dr.Sayeedur Rumi
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapyDr Kumar
 
JNC 8 guideline to Management of Hypertension
JNC 8 guideline to Management of HypertensionJNC 8 guideline to Management of Hypertension
JNC 8 guideline to Management of HypertensionPranav Sopory
 
Management of acute asthma in adults
Management of acute asthma in adultsManagement of acute asthma in adults
Management of acute asthma in adultsAshraf ElAdawy
 

What's hot (20)

Sepsis
SepsisSepsis
Sepsis
 
Spontaneous Bacterial peritonitis
Spontaneous Bacterial peritonitisSpontaneous Bacterial peritonitis
Spontaneous Bacterial peritonitis
 
HYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCYHYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCY
 
catheter related blood stream infections-complete material
catheter related blood stream infections-complete materialcatheter related blood stream infections-complete material
catheter related blood stream infections-complete material
 
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EHAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
 
Principles of management of acute heart failure
Principles of management of acute heart failurePrinciples of management of acute heart failure
Principles of management of acute heart failure
 
hemodialysis catheter infection
hemodialysis catheter infectionhemodialysis catheter infection
hemodialysis catheter infection
 
Sepsis
SepsisSepsis
Sepsis
 
RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS(RPGN)
RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS(RPGN)RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS(RPGN)
RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS(RPGN)
 
Sepsis 3.0
Sepsis 3.0Sepsis 3.0
Sepsis 3.0
 
Fever of unkown origin
Fever of unkown originFever of unkown origin
Fever of unkown origin
 
Venous Thromboembolism
Venous ThromboembolismVenous Thromboembolism
Venous Thromboembolism
 
Heparin Induced Thrombocytopeia (HIT)
Heparin Induced Thrombocytopeia (HIT)Heparin Induced Thrombocytopeia (HIT)
Heparin Induced Thrombocytopeia (HIT)
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Febrile neutropenia
Febrile neutropeniaFebrile neutropenia
Febrile neutropenia
 
JNC 8 guideline to Management of Hypertension
JNC 8 guideline to Management of HypertensionJNC 8 guideline to Management of Hypertension
JNC 8 guideline to Management of Hypertension
 
Ventilator Associated Pneumonia (VAP) or Hospital Acquired Pneumonia (HAP)
Ventilator Associated Pneumonia (VAP) or Hospital Acquired Pneumonia (HAP)Ventilator Associated Pneumonia (VAP) or Hospital Acquired Pneumonia (HAP)
Ventilator Associated Pneumonia (VAP) or Hospital Acquired Pneumonia (HAP)
 
Atrial Fibrillation
Atrial FibrillationAtrial Fibrillation
Atrial Fibrillation
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Management of acute asthma in adults
Management of acute asthma in adultsManagement of acute asthma in adults
Management of acute asthma in adults
 

Similar to Management of Skin and Soft Tissue Infections: IDSA Guideline 2014

Skin soft tissue care guide
Skin soft tissue care guideSkin soft tissue care guide
Skin soft tissue care guideDaniel Garcia
 
CHRONIC Staphylococcus aureus infection - 2014 jan31 - VRSA
CHRONIC Staphylococcus aureus infection - 2014 jan31 - VRSACHRONIC Staphylococcus aureus infection - 2014 jan31 - VRSA
CHRONIC Staphylococcus aureus infection - 2014 jan31 - VRSANot Relevant
 
Antibiotic in ED
Antibiotic in EDAntibiotic in ED
Antibiotic in EDEM OMSB
 
Brain Abscess - Algorithmic approach
Brain Abscess - Algorithmic approachBrain Abscess - Algorithmic approach
Brain Abscess - Algorithmic approachsuresh Bishokarma
 
Infections in geriatrics
Infections in geriatricsInfections in geriatrics
Infections in geriatricsAhmedMajid19
 
Guidelines of febrile neutropenia
Guidelines of febrile neutropeniaGuidelines of febrile neutropenia
Guidelines of febrile neutropeniaMarwa Khalifa
 
Approach to the therapy of cap , vap and hap
Approach to  the therapy of cap , vap and hapApproach to  the therapy of cap , vap and hap
Approach to the therapy of cap , vap and hapazza mokhtar
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Gamal Agmy
 
Community acquired pneumonia 2015 part 2
Community acquired pneumonia  2015  part 2Community acquired pneumonia  2015  part 2
Community acquired pneumonia 2015 part 2samirelansary
 
Community acquired pneumonia 2015 part 2
Community acquired pneumonia  2015  part 2Community acquired pneumonia  2015  part 2
Community acquired pneumonia 2015 part 2samirelansary
 
Febrile neutropenia ankur
Febrile neutropenia ankurFebrile neutropenia ankur
Febrile neutropenia ankurAnkur Varshney
 
Relapsing coagulase negative staphylococcus peritonitis
Relapsing coagulase negative staphylococcus peritonitis Relapsing coagulase negative staphylococcus peritonitis
Relapsing coagulase negative staphylococcus peritonitis Ahmed Mostafa Taha Borham
 
Febrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsFebrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsAli Musavi
 
Management of infections in immunocompromised patients
Management of infections in immunocompromised patientsManagement of infections in immunocompromised patients
Management of infections in immunocompromised patientsSujay Iyer
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaNilesh Kucha
 

Similar to Management of Skin and Soft Tissue Infections: IDSA Guideline 2014 (20)

Skin soft tissue care guide
Skin soft tissue care guideSkin soft tissue care guide
Skin soft tissue care guide
 
CHRONIC Staphylococcus aureus infection - 2014 jan31 - VRSA
CHRONIC Staphylococcus aureus infection - 2014 jan31 - VRSACHRONIC Staphylococcus aureus infection - 2014 jan31 - VRSA
CHRONIC Staphylococcus aureus infection - 2014 jan31 - VRSA
 
Febrile neutropaenia
Febrile neutropaeniaFebrile neutropaenia
Febrile neutropaenia
 
Mrsa
MrsaMrsa
Mrsa
 
Antibiotic in ED
Antibiotic in EDAntibiotic in ED
Antibiotic in ED
 
Brain Abscess - Algorithmic approach
Brain Abscess - Algorithmic approachBrain Abscess - Algorithmic approach
Brain Abscess - Algorithmic approach
 
Infections in geriatrics
Infections in geriatricsInfections in geriatrics
Infections in geriatrics
 
Guidelines of febrile neutropenia
Guidelines of febrile neutropeniaGuidelines of febrile neutropenia
Guidelines of febrile neutropenia
 
Approach to the therapy of cap , vap and hap
Approach to  the therapy of cap , vap and hapApproach to  the therapy of cap , vap and hap
Approach to the therapy of cap , vap and hap
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
 
Community acquired pneumonia 2015 part 2
Community acquired pneumonia  2015  part 2Community acquired pneumonia  2015  part 2
Community acquired pneumonia 2015 part 2
 
Community acquired pneumonia 2015 part 2
Community acquired pneumonia  2015  part 2Community acquired pneumonia  2015  part 2
Community acquired pneumonia 2015 part 2
 
Febrile neutropenia ankur
Febrile neutropenia ankurFebrile neutropenia ankur
Febrile neutropenia ankur
 
strategies LTX.pptx
strategies LTX.pptxstrategies LTX.pptx
strategies LTX.pptx
 
Relapsing coagulase negative staphylococcus peritonitis
Relapsing coagulase negative staphylococcus peritonitis Relapsing coagulase negative staphylococcus peritonitis
Relapsing coagulase negative staphylococcus peritonitis
 
Febrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsFebrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patients
 
MRSA AN UPDATE
MRSA  AN UPDATE MRSA  AN UPDATE
MRSA AN UPDATE
 
Sepsis guidelines 2013
Sepsis guidelines 2013Sepsis guidelines 2013
Sepsis guidelines 2013
 
Management of infections in immunocompromised patients
Management of infections in immunocompromised patientsManagement of infections in immunocompromised patients
Management of infections in immunocompromised patients
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropenia
 

More from Sun Yai-Cheng

COVID-19 (Coronavirus disease 2019), part 2
COVID-19 (Coronavirus disease 2019), part 2COVID-19 (Coronavirus disease 2019), part 2
COVID-19 (Coronavirus disease 2019), part 2Sun Yai-Cheng
 
COVID-19 (Coronavirus disease 2019) update
COVID-19 (Coronavirus disease 2019) updateCOVID-19 (Coronavirus disease 2019) update
COVID-19 (Coronavirus disease 2019) updateSun Yai-Cheng
 
Initial Care of the Severely Injured Patient
Initial Care of the Severely Injured PatientInitial Care of the Severely Injured Patient
Initial Care of the Severely Injured PatientSun Yai-Cheng
 
Management of Heart Failure in ED
Management of Heart Failure in EDManagement of Heart Failure in ED
Management of Heart Failure in EDSun Yai-Cheng
 
2018 Stroke Guidelines
2018 Stroke Guidelines2018 Stroke Guidelines
2018 Stroke GuidelinesSun Yai-Cheng
 
DAWN and DEFUSE 3 trial
DAWN and DEFUSE 3 trialDAWN and DEFUSE 3 trial
DAWN and DEFUSE 3 trialSun Yai-Cheng
 
ATLS 10th Edition Compendium of Change
ATLS 10th Edition Compendium of ChangeATLS 10th Edition Compendium of Change
ATLS 10th Edition Compendium of ChangeSun Yai-Cheng
 
The European Guideline on Management of Major Bleeding and Coagulopathy Follo...
The European Guideline on Management of Major Bleeding and Coagulopathy Follo...The European Guideline on Management of Major Bleeding and Coagulopathy Follo...
The European Guideline on Management of Major Bleeding and Coagulopathy Follo...Sun Yai-Cheng
 
Surviving Sepsis Guidelines 2016
Surviving Sepsis Guidelines 2016Surviving Sepsis Guidelines 2016
Surviving Sepsis Guidelines 2016Sun Yai-Cheng
 
VBG or ABG analysis in Emergency Care?
VBG or ABG analysis in Emergency Care?VBG or ABG analysis in Emergency Care?
VBG or ABG analysis in Emergency Care?Sun Yai-Cheng
 
Top 10 Myths Regarding the Diagnosis and Treatment of UTI
Top 10 Myths Regarding the Diagnosis and Treatment of UTITop 10 Myths Regarding the Diagnosis and Treatment of UTI
Top 10 Myths Regarding the Diagnosis and Treatment of UTISun Yai-Cheng
 
ACEP Policy for Fever Infants and Children Younger than 2 Years of Age in ED
ACEP Policy for Fever Infants and Children Younger than 2 Years of Age in EDACEP Policy for Fever Infants and Children Younger than 2 Years of Age in ED
ACEP Policy for Fever Infants and Children Younger than 2 Years of Age in EDSun Yai-Cheng
 
Focused Cardiac Ultrasound
Focused Cardiac UltrasoundFocused Cardiac Ultrasound
Focused Cardiac UltrasoundSun Yai-Cheng
 
Post–Cardiac Arrest Care
Post–Cardiac Arrest CarePost–Cardiac Arrest Care
Post–Cardiac Arrest CareSun Yai-Cheng
 
2015 AHA CPR & ECC 更新重點提要
2015 AHA CPR & ECC 更新重點提要2015 AHA CPR & ECC 更新重點提要
2015 AHA CPR & ECC 更新重點提要Sun Yai-Cheng
 
2015 AHA/ASA Focused Update Guidelines for Acute Ischemic Stroke Regarding En...
2015 AHA/ASA Focused Update Guidelines for Acute Ischemic Stroke Regarding En...2015 AHA/ASA Focused Update Guidelines for Acute Ischemic Stroke Regarding En...
2015 AHA/ASA Focused Update Guidelines for Acute Ischemic Stroke Regarding En...Sun Yai-Cheng
 
Best Mobile Medical Apps in ED
Best Mobile Medical Apps in EDBest Mobile Medical Apps in ED
Best Mobile Medical Apps in EDSun Yai-Cheng
 
Use of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP Policy
Use of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP PolicyUse of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP Policy
Use of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP PolicySun Yai-Cheng
 
Evaluation and Management of Acute Aortic Dissection: ACEP Policy
Evaluation and Management of  Acute Aortic Dissection: ACEP PolicyEvaluation and Management of  Acute Aortic Dissection: ACEP Policy
Evaluation and Management of Acute Aortic Dissection: ACEP PolicySun Yai-Cheng
 

More from Sun Yai-Cheng (20)

COVID-19 (Coronavirus disease 2019), part 2
COVID-19 (Coronavirus disease 2019), part 2COVID-19 (Coronavirus disease 2019), part 2
COVID-19 (Coronavirus disease 2019), part 2
 
COVID-19 (Coronavirus disease 2019) update
COVID-19 (Coronavirus disease 2019) updateCOVID-19 (Coronavirus disease 2019) update
COVID-19 (Coronavirus disease 2019) update
 
Initial Care of the Severely Injured Patient
Initial Care of the Severely Injured PatientInitial Care of the Severely Injured Patient
Initial Care of the Severely Injured Patient
 
Management of Heart Failure in ED
Management of Heart Failure in EDManagement of Heart Failure in ED
Management of Heart Failure in ED
 
2018 Stroke Guidelines
2018 Stroke Guidelines2018 Stroke Guidelines
2018 Stroke Guidelines
 
DAWN and DEFUSE 3 trial
DAWN and DEFUSE 3 trialDAWN and DEFUSE 3 trial
DAWN and DEFUSE 3 trial
 
ATLS 10th Edition Compendium of Change
ATLS 10th Edition Compendium of ChangeATLS 10th Edition Compendium of Change
ATLS 10th Edition Compendium of Change
 
The European Guideline on Management of Major Bleeding and Coagulopathy Follo...
The European Guideline on Management of Major Bleeding and Coagulopathy Follo...The European Guideline on Management of Major Bleeding and Coagulopathy Follo...
The European Guideline on Management of Major Bleeding and Coagulopathy Follo...
 
Surviving Sepsis Guidelines 2016
Surviving Sepsis Guidelines 2016Surviving Sepsis Guidelines 2016
Surviving Sepsis Guidelines 2016
 
VBG or ABG analysis in Emergency Care?
VBG or ABG analysis in Emergency Care?VBG or ABG analysis in Emergency Care?
VBG or ABG analysis in Emergency Care?
 
Top 10 Myths Regarding the Diagnosis and Treatment of UTI
Top 10 Myths Regarding the Diagnosis and Treatment of UTITop 10 Myths Regarding the Diagnosis and Treatment of UTI
Top 10 Myths Regarding the Diagnosis and Treatment of UTI
 
ACEP Policy for Fever Infants and Children Younger than 2 Years of Age in ED
ACEP Policy for Fever Infants and Children Younger than 2 Years of Age in EDACEP Policy for Fever Infants and Children Younger than 2 Years of Age in ED
ACEP Policy for Fever Infants and Children Younger than 2 Years of Age in ED
 
Focused Cardiac Ultrasound
Focused Cardiac UltrasoundFocused Cardiac Ultrasound
Focused Cardiac Ultrasound
 
ACLS 2015
ACLS 2015ACLS 2015
ACLS 2015
 
Post–Cardiac Arrest Care
Post–Cardiac Arrest CarePost–Cardiac Arrest Care
Post–Cardiac Arrest Care
 
2015 AHA CPR & ECC 更新重點提要
2015 AHA CPR & ECC 更新重點提要2015 AHA CPR & ECC 更新重點提要
2015 AHA CPR & ECC 更新重點提要
 
2015 AHA/ASA Focused Update Guidelines for Acute Ischemic Stroke Regarding En...
2015 AHA/ASA Focused Update Guidelines for Acute Ischemic Stroke Regarding En...2015 AHA/ASA Focused Update Guidelines for Acute Ischemic Stroke Regarding En...
2015 AHA/ASA Focused Update Guidelines for Acute Ischemic Stroke Regarding En...
 
Best Mobile Medical Apps in ED
Best Mobile Medical Apps in EDBest Mobile Medical Apps in ED
Best Mobile Medical Apps in ED
 
Use of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP Policy
Use of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP PolicyUse of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP Policy
Use of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP Policy
 
Evaluation and Management of Acute Aortic Dissection: ACEP Policy
Evaluation and Management of  Acute Aortic Dissection: ACEP PolicyEvaluation and Management of  Acute Aortic Dissection: ACEP Policy
Evaluation and Management of Acute Aortic Dissection: ACEP Policy
 

Recently uploaded

call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingArunagarwal328757
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 

Recently uploaded (20)

call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, Pricing
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 

Management of Skin and Soft Tissue Infections: IDSA Guideline 2014

  • 1. IDSA GUIDELINES Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America Clinical Infectious Diseases 2014; 59(2):147–59
  • 2. What Is the Appropriate Evaluation and Treatment for Purulent SSTIs (Cutaneous Abscesses, Furuncles, Carbuncles, and Inflamed Epidermoid Cysts)?
  • 3.
  • 4. Gram stain and culture of pus from carbuncles and abscesses are recommended, but treatment without these studies is reasonable in typical cases (strong, moderate).
  • 5. Gram stain and culture of pus from inflamed epidermoid cysts are not recommended (strong, moderate).
  • 6. Incision and drainage is the recommended treatment for inflamed epidermoid cysts, carbuncles, abscesses, and large furuncles, mild (strong, high).
  • 7. The decision to administer antibiotics directed against S. aureus as an adjunct to incision and drainage should be made based upon presence or absence of systemic inflammatory response syndrome (SIRS), such as temperature >38℃ or <36℃, tachypnea >24 bpm, tachycardia >90 bpm, or WBC >12000 or < 400 cells/μL (moderate) (strong, low). An antibiotic active against MRSA is recommended for patients with carbuncles or abscesses who have failed initial antibiotic treatment or have markedly impaired host defenses or in patients with SIRS and hypotension (severe) (strong, low).
  • 8.
  • 9.
  • 10.
  • 11. What Is Appropriate for the Evaluation and Treatment of Erysipelas and Cellulitis?
  • 12. Cultures of blood or cutaneous aspirates, biopsies, or swabs are not routinely recommended (strong, moderate).
  • 13. Cultures of blood are recommended (strong, moderate), and cultures and microscopic examination of cutaneous aspirates, biopsies, or swabs should be considered in patients with malignancy on chemotherapy, neutropenia, severe cell-mediated immunodeficiency, immersion injuries, and animal bites (weak, moderate).
  • 14. Typical cases of cellulitis without systemic signs of infection should receive an antimicrobial agent that is active against streptococci (mild) (strong, moderate). For cellulitis with systemic signs of infection (moderate nonpurulent), systemic antibiotics are indicated. Many clinicians could include coverage against MSSA (weak, low). For patients whose cellulitis is associated with penetrating trauma, evidence of MRSA infection elsewhere, nasal colonization with MRSA, injection drug use, or SIRS (severe nonpurulent), vancomycin or another antimicrobial effective against both MRSA and streptococci is recommended (strong, moderate). In severely compromised patients (severe nonpurulent), broad-spectrum antimicrobial coverage may be considered (weak, moderate). Vancomycin plus either piperacillin-tazobactam or imipenem/meropenem is recommended as a reasonable empiric regimen for severe infections (strong, moderate).
  • 15. The recommended duration of antimicrobial therapy is 5 days, but treatment should be extended if the infection has not improved within this time period (strong, high).
  • 16. In lower-extremity cellulitis, clinicians should carefully examine the interdigital toe spaces because treating fissuring, scaling, or maceration may eradicate colonization with pathogens and reduce the incidence of recurrent infection (strong, moderate).
  • 17. Outpatient therapy is recommended for patients who do not have SIRS, altered mental status, or hemodynamic instability (mild nonpurulent) (strong, moderate). Hospitalization is recommended if there is concern for a deeper or necrotizing infection, for patients with poor adherence to therapy, for infection in a severely immunocompromised patient, or if outpatient treatment is failing (moderate or severe nonpurulent) (strong, moderate).
  • 18. Should Anti-inflammatory Agents Be Used to Complement Antibiotic Treatment of Cellulitis?
  • 19. Systemic corticosteroids (eg, prednisone 40 mg daily for 7 days) could be considered in nondiabetic adult patients with cellulitis (weak, moderate).
  • 20. What Is the Preferred Evaluation and Management of Patients With Recurrent Cellulitis?
  • 21. Identify and treat predisposing conditions such as edema, obesity, eczema, venous insufficiency, and toe web abnormalities (strong, moderate). These practices should be performed as part of routine patient care and certainly during the acute stage of cellulitis (strong, moderate).
  • 22. Administration of prophylactic antibiotics, such as oral penicillin or erythromycin bid for 4–52 weeks, or intramuscular benzathine penicillin every 2–4 weeks, should be considered in patients who have 3–4 episodes of cellulitis per year despite attempts to treat or control predisposing factors (weak, moderate). This program should be continued so long as the predisposing factors persist (strong, moderate).
  • 23. What Is the Preferred Management of Surgical Site Infections?
  • 24.
  • 25. Suture removal plus I&D should be performed for surgical site infections (strong, low).
  • 26. Adjunctive systemic antimicrobial therapy is not routinely indicated, but in conjunction with I&D may be beneficial for surgical site infections associated with a significant systemic response, such as erythema and induration extending >5 cm from the wound edge, temperature>38.5℃, heart rate >110 bpm, or WBC >12 000/μL (weak, low).
  • 27. A brief course of systemic antimicrobial therapy is indicated in patients with surgical site infections following clean operations on the trunk, head and neck, or extremities that also have systemic signs of infection (strong, low).
  • 28. A first-generation cephalosporin or an anti-staphylococcal penicillin for MSSA, or vancomycin, linezolid, daptomycin, telavancin, or ceftaroline where risk factors for MRSA are high (nasal colonization, prior MRSA infection, recent hospitalization, recent antibiotics), is recommended (strong, low).
  • 29. Agents active against gram-negative bacteria and anaerobes, such as a cephalosporin or fluoroquinolone in combination with metronidazole, are recommended for infections following operations on the axilla, GI tract, perineum, or female genital tract (strong, low).
  • 30.
  • 31. What Is the Preferred Evaluation and Treatment of Necrotizing Fasciitis, Including Fournier Gangrene?
  • 32. Prompt surgical consultation is recommended for patients with aggressive infections associated with signs of systemic toxicity or suspicion of necrotizing fasciitis or gas gangrene (severe nonpurulent) (strong, low).
  • 33. Empiric antibiotic treatment should be broad (eg, vancomycin or linezolid plus piperacillin-tazobactam or a carbapenem; or plus ceftriaxone and metronidazole), as the etiology can be poly-microbial (mixed aerobic–anaerobic microbes) or mono-microbial (group A streptococci, community-acquired MRSA) (strong, low).
  • 34. Penicillin plus clindamycin is recommended for treatment of documented group A streptococcal necrotizing fasciitis (strong, low).
  • 35.
  • 36. What Is the Appropriate Approach to the Management of Pyomyositis?
  • 37. MRI is the recommended imaging modality for establishing the diagnosis of pyomyositis. CT and ultrasound studies are also useful (strong, moderate).
  • 38. Cultures of blood and abscess material should be obtained (strong, moderate).
  • 39. Vancomycin is recommended for initial empirical therapy. An agent active against enteric gram-negative bacilli should be added for infection in immuno-compromised patients or following open trauma to the muscles (strong, moderate).
  • 40. Cefazolin or anti-staphylococcal penicillin (eg, nafcillin or oxacillin) is recommended for treatment of pyomyositis caused by MSSA (strong, moderate).
  • 41. Early drainage of purulent material should be performed (strong, high).
  • 42. Repeat imaging studies should be performed in the patient with persistent bacteremia to identify undrained foci of infection (strong, low).
  • 43. Antibiotics should be administered intravenously initially, but once the patient is clinically improved, oral antibiotics are appropriate for patients in whom bacteremia cleared promptly and there is no evidence of endocarditis or metastatic abscess. Two to 3 weeks of therapy is recommended (strong, low).
  • 44. What Is the Appropriate Approach to the Evaluation and Treatment of Clostridial Gas Gangrene or Myonecrosis?
  • 45. Urgent surgical exploration of the suspected gas gangrene site and surgical debridement of involved tissue should be performed (severe nonpurulent) (strong, moderate).
  • 46. In the absence of a definitive etiologic diagnosis, broadspectrum treatment with vancomycin plus either piperacillin/tazobactam, ampicillin/sulbactam, or a carbapenem antimicrobial is recommended (strong, low). Definitive antimicrobial therapy with penicillin and clindamycin is recommended for treatment of clostridial myonecrosis (strong, low).
  • 47. Hyperbaric oxygen (HBO) therapy is not recommended because it has not been proven as a benefit to the patient and may delay resuscitation and surgical debridement (strong, low).
  • 48. What Is the Role of Preemptive Antimicrobial Therapy to Prevent Infection for Dog or Cat Bites?
  • 49. Preemptive early antimicrobial therapy for 3–5 days is recommended for patients who a) are immunocompromised b) are asplenic c) have advanced liver disease d) have preexisting or resultant edema of the affected area e) have moderate to severe injuries, especially to the hand or face f) have injuries that may have penetrated the periosteum or joint capsule (strong, low).
  • 50. Postexposure prophylaxis for rabies may be indicated;consultation with local health officials is recommended to determine if vaccination should be initiated (strong, low).
  • 51. What Is the Treatment for Infected Animal Bite–Related Wounds?
  • 52. An antimicrobial agent or agents active against both aerobic and anaerobic bacteria such as amoxicillin-clavulanate should be used (strong, moderate).
  • 53.
  • 54. Should Tetanus Toxoid Be Administered for Animal Bite Wounds?
  • 55. Tetanus toxoid should be administered to patients without toxoid vaccination within 10 years. Tetanus, diptheria, and tetanus (Tdap) is preferred over Tetanus and diptheria (Td) if the former has not been previously given (strong, low).
  • 56. In Which Patients Is Primary Wound Closure Appropriate for Animal Bite Wounds?
  • 57. Primary wound closure is not recommended for wounds, with the exception of those to the face, which should be managed with copious irrigation, cautious debridement, and preemptive antibiotics (strong, low). Other wounds may be approximated (weak, low).